CD274 and neoplasm: Pembrolizumab, another PD-1 mAb, also demonstrated encouraging anti-tumor activity with acceptable safety for PD-L1 positive AGC in phase II and III trials [9, 10], where PD-L1 expression has been evaluated as combined positive score (CPS) counting both tumor cells and immune cells.